enzastaurin has been researched along with danusertib in 3 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (danusertib) | Trials (danusertib) | Recent Studies (post-2010) (danusertib) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 74 | 6 | 58 |
| Protein | Taxonomy | enzastaurin (IC50) | danusertib (IC50) |
|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | 0.0224 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.0126 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.03 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.155 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.031 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.407 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.047 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.462 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.161 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.432 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.669 | |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | 3.5 | |
| Aurora kinase B | Homo sapiens (human) | 0.0657 | |
| STE20-like serine/threonine-protein kinase | Homo sapiens (human) | 0.621 | |
| Aurora kinase C | Homo sapiens (human) | 0.061 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Alaoui-Jamali, MA; Amzil, H; Bijian, K; Lim, FPL; Miron, CE; Moitessier, N; Nivedha, AK; Su, J; Wernic, D | 1 |
3 other study(ies) available for enzastaurin and danusertib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity.
Topics: Antineoplastic Agents; Aurora Kinase A; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Hydrogen Bonding; Isoenzymes; Molecular Docking Simulation; Protein Kinase C; Protein Kinase Inhibitors; Selenium Compounds; Small Molecule Libraries; Structure-Activity Relationship; Substrate Specificity; Tumor Stem Cell Assay | 2022 |